| Certification: | ISO, FDA, Hahal, Food Manufacturing License, Business Licens |
|---|---|
| Assay Method: | HPLC, UV |
| Application Form: | Tablet, Capsule |
| Application: | Health Care Products, Medicine, Food & Beverage, Skin Care, Feed |
| State: | Powder |
| Extract Source: | Synthesis |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier Description Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent. Pharmacodynamics Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. At much higher concentrations it behaves as a noncompetitive inhibitor of plasmin similar to aminocaproic acid, a similar antifibrinolytic which is 10-fold less potent.6 Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by tranexamic acid may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1). Off-target antagonism of GABA(A) receptors may be associated with the development of convulsions and hyperexcitability following tranexamic acid administration1 - the risk appears higher with improper administration or administration during cardiovascular surgery. Consider EEG monitoring of patients with a history of seizure. |
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}